A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant Glioma
Authors:
- Masih TazhibiMTMasih Tazhibi
- Eric P. GrewalEGEric P. Grewal
- Rishab RamapriyanRRRishab Ramapriyan
- Leland G. K. RichardsonLRLeland G. K. Richardson
- Gust VandecandelaereGVGust Vandecandelaere
- Adrian KalawAKAdrian Kalaw
- Parker KotlarzPKParker Kotlarz
- Samuel J. SteuartSSSamuel J. Steuart
- Jing SunJSJing Sun
- Matthew GaffeyMGMatthew Gaffey
- Daniel P. CahillDCDaniel P. Cahill
- Julie J. MillerJMJulie J. Miller
Open Access
Abstract
IDH-mutant gliomas (IMGs) are a unique subset of diffuse gliomas that follow a relatively indolent course compared to IDH-wildtype glioblastoma (GBM) but inevitably progress, often to a higher histologic grade. Current standard therapies, including surgery, chemoradiation, and the recently approved mutant IDH inhibitor (mIDHi) vorasidenib, provide limited disease control and are not curative. Given the immunosuppressive tumor microenvironment (TME) driven by the mutant IDH enzyme and its associated oncometabolite 2-hydroxyglutarate (2-HG), novel immunotherapies offer a promising avenue for treatment. The goal of this paper is to review the main immunologic characteristics that distinguish IMG from GBM, including reduced T cell infiltration and function, fewer myeloid cells, and increased immune-dampening signaling. We also evaluate the preclinical and clinical evidence for immunotherapeutic approaches with the most potential to induce meaningful clinical activity, such as immune checkpoint inhibitors, CAR T cells, tumor vaccines, myeloid redirection, and oncolytic viruses. Despite significant advances in immunotherapy for IMG, fundamental questions persist, including optimal timing and combination strategies, mechanisms underpinning treatment resistance, and strategies to overcome the suppressive microenvironment. Future exploration of these treatment modalities, with a focus on mitigating soluble immunosuppressive factors in the TME, enhancing in situ T cell persistence, and leveraging novel antigen targets, is critical for advancing the state of therapy for this presently incurable group of tumors.Keywords
Funding Information
- The Jenny Fund (R01CA294071)
- A Shot for Life (R01CA294071)
- Swim Across America (R01CA294071)
- NIH/NCI (R01CA294071)
This publication has 102 references indexed in Scilit:
- A viral attack on brain tumors: the potential of oncolytic virus therapyJournal of NeuroVirology, 2024
- Glioma-associated macrophages: unraveling their dual role in the microenvironment and therapeutic implicationsCurrent Medicine, 2024
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Therapies for IDH-Mutant GliomasCurrent Neurology and Neuroscience Reports, 2023
- The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survivalThe American Journal of Human Genetics, 2022
- Genomic instability, inflammatory signaling and response to cancer immunotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcomaCancer, 2020
- The Microenvironmental Landscape of Brain TumorsCancer Cell, 2017
- Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastomaCancer Immunology, Immunotherapy, 2015